Senate panel hears evidence and concerns as sponsors seek psilocybin advisory board, not legalization
Loading...
Summary
House Bill 1809 would create a medical psilocybin advisory board to study feasibility for treatment-resistant depression, PTSD and substance use disorders. Supporters cited emerging trial data and veteran interest; opponents warned about Schedule I federal constraints and safety concerns in Colorado and Oregon programs.
Representative (prime sponsor) told the Senate Health and Human Services Committee that House Bill 1809 establishes a medical psilocybin advisory board to study whether a state pathway for therapeutic psilocybin could be designed safely and lawfully. The sponsor emphasized the bill does not legalize possession or recreational use and that the board’s work would be contingent on funding and federal constraints.
Clinical evidence and proponents: Dr. John Teal, a board-certified psychiatrist, summarized recent clinical research and meta-analyses indicating psilocybin-assisted psychotherapy has shown clinically significant reductions in depression symptoms, potential benefit in PTSD, and promising signals for substance-use disorders in limited trials. Dr. Teal described standardized clinical pathways — screening, supervised sessions, integration and aftercare — and cited early naturalistic data from Oregon and international experience while noting low reported adverse-event rates in structured programs.
Opposition and caution: Senators and witnesses, including Sue Hamola, raised concerns that psilocybin remains Schedule I under federal law, that some state-level programs (Colorado, Oregon) have reported increased poison-control calls and that major psychiatry organizations have urged caution pending more Phase 3 trials. Opponents asked whether a state-level advisory board could meaningfully operate given federal scheduling and potential legal exposure.
Implementation and fiscal caveats: Sponsors agreed to contingency language so DHHS would not be required to implement program provisions until sufficient funding exists; the bill’s effective date was moved to 07/01/2027 to align potential implementation with future budget cycles. DHHS legislative affairs noted potential system and position costs if the board’s recommendations lead to program development.
Next steps: The committee heard public testimony both for and against HB 1809 and requested amended contingency and implementation language; no committee vote occurred during the session.
